Relay Therapeutics Inc - ESG Rating & Company Profile powered by AI
Scroll down to the end of the webpage for potential risks for Relay Therapeutics Inc based on sector, geography and size. Other corporations in the scoring industry group for Relay Therapeutics Inc are displayedin the table. This ESG score includes seventeen United Nations SDGs including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Life below Water'.
Relay Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 1.3, social score of 3.4 and governance score of 5.3.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1234 | Quanterix Corp | 3.4 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1253 | Relay Therapeutics Inc | 3.3 | Medium |
| 1253 | Calithera Biosciences Inc | 3.3 | Medium |
| 1253 | Cara Therapeutics Inc | 3.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Relay Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Relay Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Relay Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Relay Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Relay Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Relay Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Relay Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Relay Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Relay Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Relay Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Relay Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Relay Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Relay Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Relay Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Relay Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Relay Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Relay Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Relay Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.